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Abstract
Aim Complications of gestational diabetes (GDM) can be mitigated if the diagnosis is recognized. However, some at-
risk women do not complete antenatal diagnostic oral glucose tolerance testing (OGTT). We aimed to understand
reasons contributing to non-completion, particularly to identify modifiable factors.
Methods Some 1906 women attending a tertiary UK obstetrics centre (2018–2019) were invited for OGTT based on
risk-factor assessment. Demographic information, test results and reasons for non-completion were collected from the
medical record. Logistic regression was used to analyse factors associated with non-completion.
Results Some 242 women (12.3%) did not complete at least one OGTT, of whom 32.2% (n = 78) never completed
testing. In adjusted analysis, any non-completion was associated with younger maternal age [≤ 30 years; odds ratio (OR)
2.3, 95% confidence interval (CI) 1.6–3.4; P < 0.001], Black African ethnicity (OR 2.7, 95% CI 1.2–5.5; P = 0.011),
lower socio-economic status (OR 0.9, 95% CI 0.8–1.0; P = 0.021) and higher parity (≥ 2; OR 1.8, 95% CI 1.1–2.8;
P = 0.013). Non-completion was more likely if testing indications included BMI ≥ 30 kg/m2 (OR 1.7, 95% CI 1.1–2.4;
P = 0.009) or family history of diabetes (OR 2.2, 95% CI 1.5–3.3; P < 0.001) and less likely if the indication was an
ultrasound finding (OR 0.4, 95% CI 0.2–0.9; P = 0.035). We identified a common overlapping cluster of reasons for
non-completion, including inability to tolerate test protocol (21%), social/mental health issues (22%), and difficulty
keeping track of multiple antenatal appointments (15%).
Conclusions There is a need to investigate methods of testing that are easier for high-risk groups to schedule and
tolerate, with fuller explanation of test indications and additional support for vulnerable groups.
Diabet. Med. 00, 1–8 (2020)
Introduction
Gestational diabetes (GDM) is increasing in prevalence in
many maternity populations globally, with current estimates
ranging from < 1% to 28% [1]. Poorly controlled GDM
carries risks for both mother and baby, including macroso-
mia, birth trauma and emergency Caesarean section [2–6].
The adverse impacts of both maternal hyperglycaemia and
accelerated fetal growth can be significantly reduced by
available treatment strategies if the diagnosis is made [6,7].
However, GDM diagnosis relies on women attending and
completing a relatively complicated standardized testing
protocol.
The gold standard test for GDM diagnosis in most
contexts is the oral glucose tolerance test (OGTT) [8].
Completing an OGTT relies on pregnant women attending a
morning appointment in a fasting state, drinking a fixed load
of glucose, spending at least two hours in the testing facility,
and undergoing multiple blood draws. Evidence suggests that
approximately half of women screened experience nausea
during the OGTT and a similar proportion find it stressful
[9]. In the UK, and several other European countries, such
testing is offered only to women deemed at high-risk of
GDM [10,11] due to the expense and inconvenience of the
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test protocol. Nonetheless, a proportion of women assessed
as high-risk do not complete an OGTT. If women do not
attend the appointment, or do not complete the full protocol,
this delays or prevents diagnosis and commencement of
treatment. Those who never complete the protocol remain at
risk of the high complication rates associated with undiag-
nosed GDM [7].
Previous investigations of barriers to detection and
diagnosis of GDM have focused mainly on national
healthcare system factors, for example the lack of consensus
regarding screening practices [11,12]. There are relatively
few studies investigating barriers to antenatal GDM screen-
ing from women’s perspectives. Previous work examining
attendance for universal GDM screening in Ireland suggests
non-attendance may be influenced by socio-economic fac-
tors and geographical location [13]. However, there is little
previous evidence concerning completion of risk-factor
based testing. Reasons for non-completion of antenatal
testing in high-risk women may differ from those in women
invited for universal screening. More evidence exists
regarding the determinants of engagement with GDM
treatment after diagnosis [12] and attendance at postnatal
screening. Factors associated with higher postnatal screen-
ing rates include older age, lower parity, and higher income
or education [14], as well as the proactive contacting of
women, and education programmes [15]. Key barriers to
postnatal screening that have been identified by previous
studies include: the demands of an OGTT testing protocol,
personal risk perception, lack of education about risk of
type 2 diabetes, and competing demands on maternal time
[16,17].
In this study, we aimed to understand which at-risk sectors
of the maternity population are most likely to not complete
antenatal testing, and to identify the barriers preventing
women from completing an OGTT. This would potentially
allow provision of additional support or modification of
services to improve completion rates.
Participants and methods
A cohort of 1906 pregnant women who were consecutively
invited to attend for an OGTT at a single tertiary centre in
the UK was identified from a contemporaneous database
kept to facilitate the clinical follow-up of results from all
OGTTs performed in pregnancy (January to December
2018). During the study period, 5299 women delivered at
the study centre, hence ~ 36% of the population were invited
for screening. All screening and testing procedures were
carried out in line with usual care within the study centre.
Risk factors for GDM were determined at booking
(usually performed at 11–16 weeks’ gestation), based on
the UK National Institute of Health and Clinical Excellence
(NICE) guideline [10]. In the study centre, other referrals for
OGTT were also made on clinical grounds and all pregnant
women were offered a random plasma glucose check at
booking with urine dip for glycosuria performed at the same
visit.
Indications for testing were categorized as follows for the
analysis: BMI ≥ 30 kg/m2, high-risk ethnicity (Black African,
Asian or other ethnicities with a high prevalence of diabetes),
family history (having a first-degree relative with type 1 or
type 2 diabetes), screening test results (raised random plasma
glucose > 7.0 mmol/l or glycosuria), maternal obstetric
history [previous macrosomic baby weighing ≥ 4.5 kg or
large-for-gestational-age (LGA), previous shoulder dystocia,
IVF pregnancy] or medical history (previous bariatric
surgery, maternal medication requirements, polycystic ovary
syndrome).
Women with any of these indications were referred for a
75-g 2-h OGTT, which occurred at 24–28 weeks. Women
attended the testing centre following an overnight fast and
had a fasting blood sample taken. They drank a standardized
75 g glucose drink provided, then had repeat blood draws at
60 and 120 min. The diagnostic criteria for GDM were
based upon modified criteria of the International Association
of the Diabetes in Pregnancy Study Groups (IADPSG) (75-g
OGTT 0 h ≥ 5.3; 1 h ≥10.0 mmol/l; 2-h ≥ 8.5 mmol/l).
We excluded women with a history of GDM in a previous
pregnancy, who were seen in clinic soon after booking and
commenced on self-monitoring of capillary blood glucose, as
recommended by NICE [10]. Women whose pregnancies
ended prior to the planned test date were also excluded from
the cohort.
Additional OGTTs were performed later in pregnancy on
an ad hoc basis where clinically indicated; for example, where
ultrasound scans later in pregnancy indicated polyhydram-
nios, high abdominal circumference or LGA. These indica-
tions were categorized as scan findings and other ad hoc
indications for the analysis. In our cohort, the majority (74%)
of GDM diagnoses were made between 24 and 28 weeks.
Women who met any of the screening criteria for an OGTT
were sent an appointment via post (with instructions regarding
how this could be rearranged via telephone if necessary). They
What’s new?
• Gestational diabetes is associated with significant com-
plications if untreated, yet a proportion of at-risk
women invited for antenatal screening do not complete
testing. There is a lack of evidence to guide improve-
ments in antenatal screening completion.
• Younger women and those from minority ethnic groups
were less likely to complete testing. Key barriers to
completion cited by women related to the demands of
the testing protocol, ability to attend appointments, and
mental health or social issues.
• Modification of testing protocols, increased support for
vulnerable groups, and fuller explanation regarding test
indications and risk could improve screening rates.
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also had the option to attend or telephone the phlebotomy
clinic directly to arrange an appointment on a convenient day.
Full instructions regarding the test protocol were sent to
women alongside the appointment confirmation letter.
If women attended the appointment but were unable to
complete the full protocol (e.g. due to experiencing vomiting
after drinking the glucose load or not following the instruc-
tions regarding fasting) this was recorded contemporane-
ously and testing rebooked.
All test results following planned OGTTs were reviewed by
specialist midwives in the obstetric centre whose practice
focuses solely on women with or at-risk of diabetes in
pregnancy. Women with positive results were contacted via
telephone and asked to attend the next available appointment
(usually within a few days) to discuss their diagnosis and
initiate treatment. Women with negative results were sent a
standard letter via post. Where no result was entered for a
planned test, midwives contacted the woman via telephone.
During this conversation, all reasons given by the woman for
non-completion of testing were recorded in the woman’s own
words by the midwives in the electronic medical record. The
appointment was then rebooked at a time and date agreed
with the woman. A letter confirming the rebooking and test
instructions was sent following the telephone conversation. If
it was not possible to contact the woman via telephone after
repeated attempts, then this was recorded as ‘no reason given’
and a letter was sent with another appointment.
Detailed data regarding maternal, pregnancy and delivery
characteristics were extracted retrospectively from the
electronic medical record. Available maternal characteris-
tics included maternal age, maternal BMI (measured at
first-trimester booking), parity (collapsed into categories as
0, 1 and ≥ 2), and ethnicity (collapsed into broad
categories: White European, Black African, Asian and
other ethnicity). Index of multiple deprivation (IMD) in
deciles was derived from postcode data, using 2019 English
indices of deprivation data [18]. The distance that each
woman lived in miles from the hospital was calculated
using UK postcode data.
All the reasons given by each woman were extracted
verbatim from the electronic medical record and then
analysed by the study team to identify common themes.
We then categorized reasons into the most common eight
themes, with any reasons not falling into these categories
classified as ‘other’. Where women gave multiple reasons for
not completing testing, all of these were included in the
analysis to capture the maximum possible information about
barriers to testing.
Three groups were considered in the analysis: women
who completed testing at their initial appointment, women
with any non-completed test (all women with one or more
non-completed OGTT) and women who never completed
testing (a subset of the former group).
Group-wise comparisons were carried out using either
Student’s t-test or the Mann–Whitney test for numerical
data, and Pearson’s chi-squared test for categorical data. We
used logistic regression to model the factors influencing
completion of testing for GDM, based on both demographic
factors and the indication for testing. Test indication models
were adjusted for maternal age and IMD decile, but not for
other factors such as BMI or ethnicity because of co-linearity
between demographic characteristics and test indications.
Venn diagrams were used to explore and visually represent
overlap and clustering of the reasons given by women for
non-completion. Findings were considered statistically sig-
nificant at an alpha level of 0.05. Power calculations were
performed post-hoc using Monte Carlo simulation, demon-
strating that key results are adequately powered. All analyses
were conducted using the R statistical software package,
version 3.5.1 [19].
The study was approved as a service evaluation by the
institution (Reasons for non-attendance at antenatal glucose
screening to identify diabetes in pregnancy; Project Record
Number 8240).
Results
Non-completion of testing
Of the 1906 women in our cohort, 87.3% (n = 1664) of
women completed testing at the initial appointment; 12.7%
(n = 242) of women did not complete at least one OGTT, of
whom 32.2% (n = 78) never completed testing (Table 1).
A diagnosis of GDM was equally likely in those who did
not complete testing on at least one occasion as in those who
completed testing at the first appointment (21 of 242, 8.7%
vs. 169 of 1664, 10.2%, P = 0.29).
Demographics of women who do not complete OGTTs
In unadjusted analysis (Table 1), any non-completion was
associated with younger maternal age (≤ 30 years,
P < 0.001), belonging to an ethnic group other than the
main categorizations (P = 0.031), having a BMI ≥ 35 kg/m2
(P = 0.009), having higher levels of deprivation (P < 0.001),
and having two or more previous children (P = 0.008). Any
non-completion was less likely in White European women
(P = 0.024). A similar set of factors was associated with
never completing GDM testing in unadjusted analysis
(Table 1).
In adjusted analysis (Table 2), any non-completed test was
associated with younger maternal age [odds ratio (OR) 2.3,
95% confidence interval (CI) 1.6–3.4; P < 0.001), being of
Black African (OR 2.7, 95% CI 1.2–5.5; P = 0.0011) or
‘other’ ethnicity (OR 1.6; 95% CI 1.1–2.3; P = 0.0017), and
higher parity (OR 1.5, 95% CI 1.0–2.3; P = 0.025 for parity
1 and OR 1.8, 95% CI 1.1–2.8; P = 0.013 for parity ≥ 2).
Women in higher socio-economic deciles were less likely to
have non-completed tests (OR 0.9, 95% CI 0.8–1.0;
P = 0.021).
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Factors associated with never completing GDM testing in
adjusted analysis (Table 2) were belonging to an ethnic group
other than the main categorizations (OR 2.4, 95% CI 1.4–
4.4; P = 0.002) and having two or more previous children
(OR 2.1, 95% CI 1.0–4.5; P = 0.015).
Non-attendance by indication for testing
Some 835 (43.8%) women had multiple indications for an
OGTT. In analysis adjusted for all categorized indications plus
maternal age and IMD decile (Table 3), there was a higher
likelihood of non-completion in women whose indications for
testing included a family history of diabetes (OR 2.2, 95% CI
1.5–3.3; P < 0.001) or a high BMI (OR 1.7, 95% CI 1.1–2.4;
P = 0.009). By contrast, women were less likely to not
complete testing if they were recommended to have an OGTT
on the basis of scan results (OR 0.4, 95% CI 0.2–0.9;
P = 0.035). There were no women who never completed
testing with scan findings or test results as an indication.
Reasons for not completing OGTTs
Women cited a variety of reasons for non-completion of
testing (Table 4). Our categorization covered the majority of
reasons given for non-completion (n = 204, 72.6%). Inabil-
ity to tolerate the testing protocol, mainly due to nausea/
vomiting associated with overnight fasting then drinking the
glucose load, was the most commonly cited reason (40 of
242, 16.5% in the group with any non-completed test).
Women also cited reasons connected to their mental health
and social issues for not completing testing (15% in the
group with any non-completed test). A number (37 of 242,
15.3%) of women who were initially scheduled for OGTT
appointments subsequently declined testing on the basis of
their general healthcare beliefs or their beliefs about preg-
nancy (22 of 242, 9.1%). These women had their informed
refusal recorded in their medical record, and none subse-
quently completed testing.
Women commonly cited more than one factor as impor-
tant in any non-completion of testing (102 of 242, 42.1%).
Multiple factors were more common in the group that never
completed testing (54 of 78, 69.2%). To explore these
clusters of reasons further, we visualized the overlap between
the top five most commonly cited reasons (Fig. 1; excluding
informed refusal, which was most commonly cited as a single
reason). From further analysis of clustering, we identified a
commonly cited triad of reasons (unable to tolerate test
protocol, social or mental health issues, and clashes with
Table 1 Key characteristics of cohort by attendance status
Category
Completed testing at
initial appointment
(n = 1664; 87%)
Any non-completed
test (n = 242; 13%) P-value
Never completed
testing (n = 78; 4.1%) P-value
GDM positive
Yes 169 (10.2) 21 (8.7) 0 (0)
No 1495 (89.8) 143 (59.1) 0 (0)
Unknown 0 (0) 78 (32.2) 78 (100)
Maternal age, years
≤ 30 480 (28.8) 110 (45.5 ) < 0.001 32 (41.0) 0.178
30–40 985 (59.2) 107 (44.2) 0.271 43 (55.1) 0.567
> 40 192 (11.5) 16 (6.6) 0.338 3 (3.8) 0.072
Unknown 7 (0.4) 9 (3.7) 0.249 0 (0) 0.435
BMI, kg/m2
≤ 25 635 (38.2) 80 (33.1) 0.219 23 (29.5) 0.178
26–35 619 (37.2) 84 (34.7) 0.425 31 (39.7) 0.644
> 35 209 (12.6) 51 (21.1) 0.009 16 (20.5) 0.028
Unknown 201 (12.1) 27 (11.2) 0.632 8 (10.3) 0.329
Ethnicity
White European 860 (51.7) 110 (45.5) 0.024 33 (42.3) 0.633
Black African 44 (2.6) 12 (5.0) 0.131 3 (3.8) 0.213
Asian 215 (12.9) 22 (9.1) 0.367 4 (5.1) 0.672
Other 353 (21.2) 69 (28.5) 0.031 30 (38.5) 0.050
Unknown 192 (11.5) 29 (12.0) 0.354 8 (10.3) 0.532
Parity
0 771 (46.3) 90 (37.2) 0.093 26 (33.3) 0.169
1 597 (35.9) 87 (36.0) 0.272 31 (39.7) 0.552
≥ 2 293 (17.6) 57 (23.6) 0.008 20 (25.6) 0.039
Unknown 3 (0.2) 8 (3.3) 0.611 1 (1.3) 0.721
IMD decile 7.3 (6.0–9.0) 6.6 (5.0–8.0) < 0.001 6.7 (5.0–8.0) 0.042
Distance from hospital (miles) 9.8 (3.2–14.2) 10.6 (3.2–15.1) 0.231 11.0 (3.3–14.9) 0.199
Variables are reported as n (%) or mean (IQR). Women who never completed testing are a subset of the group with any non-completed test.
Group-wise comparisons were carried out using either Student’s t-test or the Mann–Whitney test for numerical data, and Pearson’s chi-
squared test for categorical data. Non-completion groups were compared to the group who completed testing at initial appointment. IMD,
Index of multiple deprivation.
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other appointments; Fig. 2). Of the 22 women with
overlapping factors within this triad, only eight ever
completed testing.
Discussion
Non-completion of OGTTs puts women and babies at
risk of delayed or missed diagnosis of GDM. We have
identified key demographic factors associated with non-
completion, including younger maternal age, lower socio-
economic status, belonging to a minority ethnic group,
and higher parity. Test indication was a key predictor of
completion, with non-completion less likely if women
were invited due to scan findings and more likely if
indications included family history or high BMI. The
principal reasons for non-completion cited by women
were not being able to tolerate the test protocol, social or
mental health issues, and clashes with other appointments
or admissions.
Women from vulnerable (younger, lower socio-economic
status, and minority ethnic) groups were less likely to
complete testing. It is known that such groups are likely to
find it more difficult to access healthcare in general and to
navigate systems [20,21]. Social or mental health issues
were also reported as reasons for non-completion, further
demonstrating the need for increased support of vulnerable
women. Although the distance women lived from the test
centre was not directly correlated with non-attendance in
our cohort, a number of women cited transport and
childcare issues as barriers to attendance. A more accessible
alternative to an OGTT could improve test completion; for
example, enabling testing in the community. An Irish trial
of universal antenatal OGTT screening in primary care
previously attempted to address access barriers, but found
Table 2 Characteristics predicting non-completion of gestational diabetes testing in adjusted analysis
Category Odds of any non-completion P-value Odds of never completing P-value
Maternal age, years
≤ 30 2.3 (1.6–3.4) < 0.001 1.3 (0.8–2.5) 0.219
30–40 Reference Reference
> 40 0.8 (0.4–1.5) 0.572 0.3 (0.0–1.0) 0.104
BMI, kg/m2
≤ 25 Reference Reference
26–35 0.9 (0.6–1.3) 0.496 1.3 (0.7–2.6) 0.312
> 35 1.2 (0.7–1.8) 0.464 1.7 (0.8–3.6) 0.162
Ethnicity
White European Reference Reference
Black African 2.7 (1.2–5.5) 0.011 1.3 (0.2–4.2) 0.839
Asian 0.8 (0.4–1.5) 0.582 0.8 (0.2–1.8) 0.490
Other 1.6 (1.1–2.3) 0.017 2.4 (1.4–4.4) 0.002
Parity
0 Reference Reference
1 1.5 (1.0–2.3) 0.025 1.7 (0.9–3.1) 0.099
≥ 2 1.8 (1.1–2.8) 0.013 2.1 (1.0–4.5) 0.015
IMD decile 0.9 (0.8–1.0) 0.021 0.9 (0.8–1.0) 0.099
Distance from hospital, miles 1.00 (0.9–1.1) 0.532 1.0 (1.0–1.0) 0.564
Values are odds ratios and 95% confidence intervals. Non-completion groups were compared with the group who completed testing at the
initial appointment. Women who never completed testing are a subset of the group with any non-completed test. Models are adjusted for all
other co-variates listed in the table. IMD, Index of multiple deprivation.
Table 3 Likelihood of non-completing by indication for testing
Indication for testing Odds of any non-completion P-value Odds of never completing P-value
BMI ≥ 30 kg/m2 (n = 610) 1.7 (1.1–2.4) 0.009 1.9 (1.1–3.3) 0.028
High-risk ethnicity (n = 428) 1.4 (0.9–2.1) 0.165 0.8 (0.4–1.7) 0.638
Scan findings (n = 200) 0.4 (0.2–0.9) 0.035 Infinity
Family history (n = 452) 2.2 (1.5–3.3) <0.001 2.8 (1.6–4.9) < 0.001
Screening test results (n = 103) 0.4 (0.1–1.0) 0.110 Infinity
Maternal obstetric or medical history (n = 369) 1.3 (0.8–2.1) 0.342 1.8 (0.8–3.0) 0.131
Multiple pregnancy (n = 77) 0.8 (0.3–2.0) 0.721 1.1 (0.2–4.0) 0.864
Other indication (n = 29) 0.8 (0.1–3.1) 0.821 1.4 (0.0–7.3) 0.740
Values are odds ratios and 95% confidence intervals. Non-completion groups were compared with the group who completed testing at initial
appointment. Women who never completed testing are a subset of the group with any non-completed test. Models are adjusted for all other
co-variates listed in table, plus maternal age and Index of multiple deprivation (IMD) decile.
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screening rates were significantly lower than in secondary
care due to practical and logistical difficulties experienced
by primary care providers [22]. Recently, a self-adminis-
tered home OGTT, requiring women to complete finger-
pricks before and after drinking a glucose load, has been
trialled and shows good agreement with laboratory results
[23].
Our results also indicate that the test protocol itself
presents a significant barrier to completion. In our cohort,
not being able to tolerate the OGTT due to nausea was the
most common reason for non-completion. Several studies
have explored substituting a glucose drink with food, e.g. ice
cream, a muffin and beverage, or a specially designed
breakfast [24–26]. These studies all demonstrated significant
correlation between the results from the standard OGTT
glucose load and tests using food. Our results highlight the
urgent need for further work on better-tolerated alternative
test designs. Alternative methods of diagnosis could also be
considered, for example self-monitoring of blood glucose
[27,28].
Women invited for an OGTT on the basis of a scan result
were more likely to attend and there were no ‘never
attenders’ with this or test results as indications. By contrast,
women whose indications included family history of diabetes
were significantly less likely to complete testing. Parous
women were also significantly less likely to attend antenatal
testing, both in our cohort and a previous study [13];
however, childcare issues were only directly cited by 5.4% of
women in our cohort. Women whose previous pregnancies
had good outcomes or who have family experience with
diabetes may perceive the diagnosis of GDM differently from
primiparous women or those facing an abnormal test result.
Better understanding of risk perception among women with
different testing indications could help to improve engage-
ment, and qualitative studies would be of benefit to explore
this further. Women whose indication for testing was a high
BMI were also less likely to attend. This may relate to risk
perception, although fears of shaming or judgement could
also deter women from accessing screening. Previous studies
have explored these issues in women with high BMI
undergoing GDM treatment, who describe feeling under
surveillance and being judged as ‘good mothers’ by health-
care staff [29,30]. Clear explanations of risk factors and
Table 4 Reasons given by women for not completing oral glucose
tolerance testing
Reasons for non-completion
Any
non-completion
(n = 242)
Never
completed
(n = 78)
Access issues (transport, etc.) 14 (5.8) 8 (10.3)
Unable to tolerate test protocol 40 (16.5) 16 (20.5)
Childcare issues 13 (5.4) 5 (6.4)
Social or mental health issues 37 (15.3) 17 (21.8)
Clash with other appointments,
admissions
34 (14.0) 12 (15.4)
Instructions for test not followed 16 (6.6) 2 (2.6)
Unable to get convenient
appointment
34 (14.0) 20 (25.6)
Declined testing after discussion 22 (9.1) 22 (28.2)
Other reasons or no reason given 71 (29.3) 22 (28.2)
Values are number (% of group total) who cited each category
of reason for not completing testing. Multiple reasons were
commonly cited and all reasons cited by each woman were
included in the analysis. Women who never completed testing
are a subset of the group with any non-completed test.
FIGURE 1 Venn diagram showing the most commonly cited reasons for non-completion of antenatal oral glucose tolerance testing.
FIGURE 2 Venn diagram showing the most commonly cited triad of
reasons for non-completion, of the 22 women with overlapping factors
within this triad, only eight ever completed testing.
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GDM aetiology, using sensitive and non-judgemental lan-
guage, could potentially increase test completion.
Strengths
A large and complete contemporaneously collected data set
containing detailed demographic information was available
for analysis. A major strength of the study was that the
barriers women faced with regards to attendance were
recorded in their own words shortly after any non-completed
test by specialist midwives.
Limitations
Although our approach gives a good balance between the
narrative and quantitative aspects, further work involving in-
depth qualitative analysis would be of benefit in designing
future interventions. Data on subsequent engagement with
GDM treatment and on pregnancy outcomes were not
available, but would be of interest in improving outcomes.
The population attending our single testing centre may not
reflect specific barriers faced in other pregnancy populations
(e.g. we have less ethnic diversity than the UK as a whole),
and thus further work is required to determine the general-
izability of these findings.
Conclusions
Based on our findings we suggest three key areas for
intervention which could improve completion rates:
increased support for vulnerable groups, modification of
testing protocols, and improved communication regarding
risk. Younger women, those from lower socio-economic
status backgrounds, minority ethnic groups, and those with
mental health or social issues are likely to need additional
support to navigate systems and ensure that their pregnancy
healthcare needs are met.
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